(thirdQuint)First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR Mutation.

 Eligible patients are administered with oral icotinib 125mg three times daily for two months, in which responsive patients (partial response and stable disease) are randomized (1: 1: 1) and receive icotinib plus concurrent radiotherapy, or chemotherapy plus concurrent radiotherapy, or icotinib monotherapy.

 The primary endpoint is progression-free survival, and the incidence of radiation-induced lung injury.

.

 First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR Mutation@highlight

Eligible patients are administered with oral icotinib 125mg three times daily for two months, in which responsive patients (partial response and stable disease) are randomized (1: 1: 1) and receive icotinib plus concurrent radiotherapy, or chemotherapy plus concurrent radiotherapy, or icotinib monotherapy.

